The biopharmaceutical industry is undergoing significant digital transformation. While this shift brings exciting opportunities, it also introduces increasing complexity and growing expectations ...

The company, whose headquarters is on Innovation Way, Heslington, has also finalised a royalty agreement with its development partner, Neuro-Bio Ltd. Under the agreed terms, Aptamer is eligible to ...

Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA ...

--(BUSINESS WIRE)--#AnsaOnTimeGuarantee--Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing ...

A week ago, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed ...

Investing.com -- Shares of Adaptive Biotechnologies (NASDAQ:ADPT) surged 35% following a robust first-quarter earnings report that exceeded analyst expectations. The company reported a smaller ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ ...

(REUTERS) ITC Ltd on Thursday said it has signed a Share Purchase Agreement to acquire 100% of the share capital of Sresta Natural Bioproducts Pvt. Ltd (SNBPL), which manufactures and sells ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,200 points on Friday. Shares of Guess?, Inc. GES fell sharply in today's pre-market trading after the company ...

Ayrmid proposed acquiring Bluebird for $4.50 per share in cash plus a $6.84 per share contingent value right based on a net sales milestone. Bluebird previously agreed to a $3.00 per share buyout ...

Welcome to the CollPlant Biotechnologies investor conference call to discuss Financial Results for the Full Year and Fourth Quarter of 2024 and Corporate Updates. [Operator Instructions] As a ...